Apotex Pharmachem Inc.

Apotex Inc.

Brantford Chemicals Inc.

Carlos Zetina-Rocha

Gamini Weeratunga

Stephen E Horne

Allan W Rey

Eduardo Gustavo Cammisa

Bhaskar Reddy Guntoori

Yajun Zhao

Cameron L McPhail

Mohammed Abdul Raheem

Probal Kanti Datta

Lotfi Derdour

Keshava K S Murthy

Matthew A Buck

Disclosed are solid forms of Nilotinib hydrochloride and methods of preparation of various crystalline solvates of Nilotinib HCl including benzyl alcohol, acetic acid, propylene glycol, and isopropanol. Nilotinib HCl is a tyrosine kinase inhibitor used for the treatment of drug resistant chronic myelogenous leukemia (CML).

Solid forms of nilotinib hydrochloride

There is provided a crystalline form of Lapatinib, termed APO-I, and methods for making APO-I. There is also provided a crystalline solvate form of Lapatinib, termed APO-II, and methods for making APO-II.

Polymorphic forms of Lapatinib ditosylate and processes for their preparation

There is provided processes for preparing Lapatinib and pharmaceutically acceptable salts thereof by the reductive amination of the aldehyde of Formula II by treatment with 2-methanesulphonylethylamine followed by catalytic hydrogenation in the presence of a suitable hydrogenation catalyst.

Process for the preparation of lapatinib and its ditosylate salt

In illustrative embodiments, there is provided an amorphous form of L-arginine salt of perindopril which may be particularly suitable for pharmaceutical applications, and processes for preparing said form.

Amorphous form of an L-arginine salt of perindopril and processes for preparation thereof

The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof.

Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same

The present invention relates to new and useful processes for the preparation of the anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride.

Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride (ziprasidone hydrochloride)

This invention relates to the preparation of 3-sulfonamido-4-arylaminopyridines by heating a 3-sulfonamido-4-aminopyridine with an aryl halide in the presence of an alkaline compound, a copper-containing agent and in the presence of a polar protic solvent.

Growing community of inventors

Brantford, Canada

Carlos Zetina-Rocha